Association of T-Cell Receptor Repertoire Use With Response to Trastuzumab-Lapatinib in HER2-Positive Breast Cancer

Leggi l'articolo originale

This biomarker study estimates the diversity of T-cell populations in the tumor microenvironment by assessing messenger RNA expression of the T-cell receptor β chain variable gene from RNA sequencing data of pretreatment biopsies of women with HER2-positive breast cancer in the Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (NeoALTTO) trial.

Lascia un commento